Souhaitez-vous accéder aux communiqués récents ?

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....

  Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab The European Medicines Agency (EMA) validates Shire's Marketing Authorization...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION ...

 Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment  Research agreement focuses on evaluating a potential treatment for a lysosomal storage...

District Court Issues Ruling Finding Adderall XR® Patents Infringed Cambridge, Mass., USA - March 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that its subsidiary, Shire...

2017 Annual Report - DTR 6.3.5 and LR 9.6.1 Disclosures March 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that the following documents will today be posted to...

New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism -       Clinical and real-world data on chronic...

Director/PDMR Shareholding March 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transaction by person discharging managerial responsibilities 1. Details of the person discharging...

Shire Applies to Cease to be a Reporting Issuer in Canada Dublin, Ireland - 13 March 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the "Company") announces that it has applied to the...

Elections for the interim dividend in respect of the six months to December 31, 2017   March 12, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announced on February 14, 2018, an...